Company Information
CIN
Status
Date of Incorporation
18 March 1991
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
10 August 2023
Paid Up Capital
242,368,716
Authorised Capital
505,000,000
Directors
Krishna Prasad Chigurupati
Director/Designated Partner
over 2 years ago
over 2 years ago
Umadevi Chigurupati
Director/Designated Partner
over 2 years ago
over 2 years ago
Kandiraju Venkata Sitaramrao
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Palepu Sucharita Rao
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Saumen Chakraborty
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Sandip Neogi
Manager/Secretary
about 6 years ago
about 6 years ago
Harsha Chigurupati
Director/Designated Partner
over 6 years ago
over 6 years ago
Venkatanaga Kali Vara Prasada Raju Vetukuri
Wholetime Director
almost 9 years ago
almost 9 years ago
Krishna Murthy Ella
Director
about 16 years ago
about 16 years ago
Comandur Parthasarathy
Director
about 16 years ago
about 16 years ago
Past Directors
Kapil Mehan
Additional Director
over 2 years ago
over 2 years ago
Jyothi Prasad
Director
over 6 years ago
over 6 years ago
Robert George Cunard
Additional Director
almost 7 years ago
almost 7 years ago
Arun Sawhney
Additional Director
about 7 years ago
about 7 years ago
Karuppannan Ganesh
Cfo(kmp)
over 8 years ago
over 8 years ago
Venkata Satyanarayana Murthy Vadali
Cfo(kmp)
over 11 years ago
over 11 years ago
Basava Sankar Rao Kolli
Additional Director
almost 13 years ago
almost 13 years ago
Arun Rao Akinepally .
Additional Director
over 15 years ago
over 15 years ago
Nelson David Corda
Alternate Director
over 17 years ago
over 17 years ago
Kurian Peter Arattukulam
Director
over 22 years ago
over 22 years ago
Lakkavajjala Subrahmanyasarma
Director
almost 26 years ago
almost 26 years ago
Nagabhushan Rao Ganti
Director
over 31 years ago
over 31 years ago
Patents
The present invention relates to an improved process for the preparation of Silodosin (I) which is useful in the treatment of Benign Prostate Hyperplasia (BPH) and related disorders. The present invention also relates to the purification process resulting in substantially pure Silodosin.
ABSTRACT
The present invention relates to a process for the preparation of crystalline Form G
of tenofovir alafenamide hemifumarate .The invention further relates to pharmaceutical compositions comprising crystalline Form G of tenofovir alafenamide hemifumarate, useful in the treatment treat or prevent diseases o...
The present invention relates to improved process for the preparation of highly pure Pirfenidone (I).
Formula I
Pirfenidone (I) is an anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF).
Improved processes for the preparation of Rifaximin. Particularly, improved processes for the preparation of Rifaximin from Rifamycin O and S. More particularly a novel polymorph of Rifaximin and process for its preparation are provided.
ABSTRACT
The present invention relates to novel crystalline Form G of Dimethyl Fumarate having the following Formula I
Formula I
The present invention relates to process for the preparation of Darunavir or a solvate thereof of Formula I
using a novel intermediate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(1,3-dioxoisoindolin-2-yl)-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate Compound of formula (II):
...
Abstract A continuous or batch process for the preparation of primary and secondary N-acetylated aromatic amines or O-acetylated product of hydroxy benzoic acids
The present invention relates to continuous processes for the preparation of primary and secondary N-acetylated aromatic amines of formula I or O-acetylat...
The present invention relates to a process for the preparation of amino alcohol derivatives or salts thereof. In particular the present invention relates to process for the preparation of amino alcohol derivatives or salts thereof which may be used as intermediates in the preparation of HIV reverse transcriptase inh...
The present invention relates to a process for the preparation of crystalline Form Gl of Ertugliflozin (I).
The invention also relates to crystalline Form Gl obtained by the process of the present invention, the said Form Gl being substantially pure, stable, and characterized by X-ray powder-diffraction pattern ...
The present invention relates to improved process for the preparation of Temozolomide Formula I.
(I)
Said Temozolomide (I) is useful in the treatment of cancer.
The present invention relates to an improved process for the preparation of nucleoside derivative which are used as agents in the treatment of viral diseases. In particular, the present invention relates to process for the preparation of a nucleotide analog inhibitor of HCV NS5B polymerase.
ABSTRACT
The present invention relates to an improved process for the preparation of compounds of formula I
This intermediate is chemically designated as (E)-2-halo-3-(dimethylamino)acrylaldehyde. The compound of Formula I is a key useful intermediate in the preparation Etoricoxib.
The present invention relates to one pot process for the preparation of acetylated amino phenols from aryl nitro compounds.
ABSTRACT
The present invention relates to stable amorphous form of a HIV protease inhibitor, namely, Atazanavir. The present invention preferably relates to stable amorphous form of Atazanavir free base. The present invention also relates to an improved process for the preparation of Atazanavir sulfate from amorpho...
ABSTRACT
The present invention relates to an improved process for the preparation of DPP-IV inhibitors. In particular, the present invention relates to an improved process for the preparation of Teneligliptin. More particularly, the present invention relates to an improved process for the preparation of Teneliglipt...
The present invention relates to improved process for the preparation of gliclazide of formula I.
(I)
Gliclazide (I) is useful in the treatment of diabetic.
The present invention relates to a stable amorphous form Teneligliptin oxalate (I).
(I)
The invention also relates to stable amorphous form obtained by the process of the present invention, the said amorphous form being substantially pure.
Said amorphous form is useful in preparing pharmaceutical compositi...
ABSTRACT
The present invention relates to a commercially viable process for the preparation of Eltrombopag Olamine of formula (I)
I II
using novel commercially useful eltrombopag amine salts of formula (II).
Eltrombopag Olamine of formula (I) is useful as a thrombopoietin (TPO) receptor agonist indicat...
The present invention relates to improved process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (I).
(I)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (I) is useful as intermediate in the preparation of of anti-retroviral drugs.
The present invention relates to an improved and industrially advantageous process for the preparation of Rifaximin with high purity and yield. Particularly the present invention relates to improved processes for the preparation of Rifaximin from Rifamycin O and S. More particularly the present invention relates to ...
NOVEL POLYMORPHIC FORMS OF ((1S,2S,3S,4R,5S))-2,3,4-(TRIS-BENZYLOXY)-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)PHENYL)-6,8-DIOXA-BICYCLO[3.2.1]OCT-1-YL-METHANOL
ABSTRACT
The present invention relates to novel polymorphs of ((1S,2S,3S,4R,5S))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-ethoxy-benzyl)phenyl)-6,8-dioxa-bicyclo[3.2....
The present invention relates to an improved process for the preparation Crystalline Form G2 of Rifaximin of Formula (I).
(I)
The invention also relates to crystalline Form G2 of Rifaximin (I) obtained by the process of the present invention, the said Form G2 being substantially pure, stable and characterize...
The present invention relates to a process for the preparation of Teneligliptin oxalate
The invention also relates to stable crystalline form designated as form Gl obtained by the process of the present invention, the said crystalline form being substantially pure.
Said crystalline form is useful in preparing phar...
PIMAVANSERIN PROCESS
ABSTRACT
The present invention relates to process for the preparation of Pimavanserin of formula (I) using a novel intermediate 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl) -1-(1-methylpiperidin-4-yl)thiourea (II).
(I)
(II)
Pimavanserin (I) is useful in the treatment of Parkinson’...
The present invention relates to improved process for the preparation of Pimavanserin of formula (I)
(I)
Pimavanserin (I) is useful in the treatment of Parkinson’s disease psychosis.
The present invention relates to improved process for the preparation of Guaifenesin Formula I using Heat transfer fluids.
(I)
The present invention relates to a process for the preparation of N-(4-fluorobenzyl)- N-(1- methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)-phenylmethy)carbamide or Pimavanserin of Formula (I).
(I)
The present invention further relates to process for the purification of N-(4-fluorobenzyl)- N-(1- methylpiperidi...
The present invention relates to improved and commercially viable process for the preparation of Trientine dihydrochloride of formula I.
(I)
Trientine dihydrochloride (I) is a therapeutically useful chelating agent which is used to bind and remove excess copper in the body in order to treat Wilson"s disease,...
The present invention relates to pharmaceutical composition comprising crystalline Rifaximin, Poloxamer, Stearyl polyoxyl-32 glyceride and one or more pharmaceutically acceptable excipient(s) where in Rifaximin has average particle diameter ranging between 10-100 microns, and crystalline forms are selected from Form...
The present invention relates to a process for the preparation of crystalline Form GR of
Rifaximin (I).
(I)
The invention also relates to crystalline Form GR of Rifaximin obtained by the process of the present invention, the said Form GR being substantially pure, stable, and characterized by X-ray powder di...
A PROCESS FOR THE PARTICLE SIZE REDUCTION
ABSTRACT
Particular aspects of the present invention relates to a process for the prcpmr~tion of
pirfcnidonc (I) having partic.lc size < 2001Jm comprising the steps of: o-N;)H"
0
Formula I
a. providing a solution of Pirfenidonc in an organic solvent at temperature
...
PROCESS FOR THE PREPARATION OF D- PENICILLAMINE
ABSTRACT
The present invention relates to improved process for the preparation of D-Penicillamine of formula I.
(I)
D-Penicillamine (I) and salts thereof are well known to be useful in the treatment of Wilson’s disease, rheumatoid disease and cystinuria.
...
The present invention relates to continuous drying process for metformin, acetaminophen or their granulate composition/s by Spin Flash Drying process to manufacture pharmaceutical grade material on larger scale safer operations.
The present invention relates to commercially viable process for the preparation of Cabozantinib of formula (I) and its pharmaceutically acceptable salts for the treatment of patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC...
ABSTRACT
The present invention relates to an improved process for the preparation of Lenvatinib of formula (I) which is useful in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
(I)
The present invention also relates ...
PHARMACETICAL COMPOSITIONS OF IBUPROFEN AND FAMOTIDINE
ABSTRACT
The present invention relates to stable pharmaceutical compositions of Ibuprofen and Famotidine in a single unit dosage form. The present invention also provides trilayer tablet and tablet-in-tablet dosage forms comprising Ibuprofen and Famotidine. It...
The present invention relates to the field of Pharmaceuticals, more particularly, the invention relates to an improved process for the synthesis of Vasopressin, chemically represented by the formula (1).
The present invention relates to stable pharmaceutical compositions of Guaifenesin comprising microspheres of Guaifenesin compressed into oral dosage forms comprising two portions of guaifenesin in the form of immediate release portion and extended release portion. The present invention also relates to Guaifenesin m...
The present invention relates to an improved, industrially applicable and commercial scalable crystallization process to yield a highly pure product of Guaifenesin (Formula I) with controlled particle size distribution and an improved purity profile, wherein the process involves the use of heat liberation while crys...
This invention is directed to a method for synthesis and purification of Losartan of the formula (I), its intermediates and pharmaceutically acceptable salts and solvents thereof; also herein described are the compositions comprising substantially pure Losartan free base or salts thereof free of the well-known ...
The present invention relates to a commercially viable improved process for the preparation of Prazosin hydrochloride of formula (I) for the treatment of patients with hypertension to reduce the blood pressure as reducing the blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily stoke...
The present invention relates to Pharmaceutical composition of Ibuprofen or its pharmaceutically acceptable salt, enantiomers thereof, wherein said composition comprising 75 to 90 % by weight of Ibuprofen; 0.05% to 0.2% by weight of Sodium lauryl sulfate; 2% to 5% by weight of binder; 3% to 6% by weight of a disinte...
The present invention relates to improved pharmaceutical compositions of Pirfenidone comprising Pirfenidone and one or more pharmaceutically acceptable excipients, wherein the said composition is free of binding agent. The present invention also relates to process for preparing pharmaceutical composition of Pirfenid...
ABSTRACT
The present invention relates to an improved and commercially viable process for the preparation of Lapatinib (I) and its salts, wherein the impurities in particular the isomeric impurities of compound of Formula IIIa and Formula IIIb are controlled and found to be absent, or below the level of detection ...
The present invention relates to the field of Pharmaceuticals and chemistry; more particularly, the invention relates to an improved process for synthesis of a commercially scalable, solid powder form of Levocetirizine and Cetirizine base which is chemically represented by the formula I and II respectively.
2-[...
AN IMPROVED PROCESS FOR THE PREPARATION OF SARTAN, FREE OF GENOTOXIC AZIDE IMPURITIES
The present invention relates to the synthesis and purification of Losartan of the Formula (I), its intermediates and pharmaceutically acceptable salts and solvates thereof; also herein described are precise reaction conditio...
CONTINUOUS METHOD FOR MANUFACTURING P-AMINO PHENOL AND DERIVATIVES THEREOF
The present invention relates to a continuous process for the preparation and purification of p-Aminophenol (PAP) from nitrobenzene by use of catalytic hydrogenation wherein a loop Venturi reactor is employed, which results in creating ...
AN IMPROVED PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN, FREE OF ACID AND FURANOSE IMPURITIES
The present invention is to provide an improved process for the synthesis of amorphous Dapagliflozin of formula I through Dapagliflozin (S/RS)-1,2-propanediol, wherein the process yields substantially pure product fr...
AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED BI-PHENYL CARBOXYLIC ACID COMPOUND AND IT’S USE IN THE PREPARATION OF ELTROMBOPAG
ABSTRACT
The present invention relates to an improved process for the preparation of Substituted Bi-Phenyl Carboxylic Acid Compound. More specifically it relates to a process f...
AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB
ABSTRACT
The main objective of the present invention is to improve the process for the preparation of ruxolitinib using protected (E)-N-(3-(Dimethylamino)-2-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) allylidene)-N-methylmethanaminium chloride hydrochloride and (R)-...
AN IMPROVED PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN, FREE OF ACID AND FURANOSE IMPURITIES
The present invention is to provide an improved process for the synthesis of Empagliflozin, wherein the process yields substantially pure product free of the acid and furanose impurities, further which involve singl...
ABSTRACT
“NOVEL CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE SALTS”
The present invention relates to novel crystalline forms of tenofovir alafenamide salts and process for the preparation thereof. More, particularly the present invention relates to novel crystalline form of tenofovir alafenamide hemi maleate, ...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF VILOXAZINE HYDROCHLORIDE:
The present invention relates to an improved process for the preparation of Viloxazine hydrochloride of formula I with high yield and purity.
Formula I
Dated this: 28th day of March, 2024.
...
ABSTRACT
METHOD OF MANUFACTURING OF DICYANDIAMIDE:
The present invention generally relates to a method of manufacture of Dicyandiamide (popularly known in industry as DCDA), and in particular it relates to an energy efficient, two step, green method of manufacture of Dicyandiamide.
Dated this 16th day of May,...
ABSTRACT
IMMOBILISED WHOLE CELL NITRILASES FOR BIOCATALYSIS OF GABAPENTIN INTERMEDIATE:
The present invention relates to immobilization of whole cell having nitrilase activity by cross-linked cell aggregates (CLCAs) and the use of such immobilized whole cell nitrilase enzymes for nitrile biocatalysis of gabapent...
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB AND NOVEL CRYSTALLINE FORM THEREOF:
The present invention relates to an improved process for the preparation of ruxolitinib or its salts and intermediates thereof. The present invention also relates to a novel crystalline form G of ruxolitinib, a process...
ABSTRACT
ONE-POT PROCESS FOR THE PREPARATION OF GABAPENTIN INTERMEDIATE
The present invention provides a one-pot process for the preparation of 1-(cyanomethyl) cyclohexane-1-carbonitrile, which is a key intermediate for preparation of gabapentin. Particularly, the present invention provides a one-pot process f...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF 5-BROMO-4-(4- CHLOROTHIOPHEN-2-YL)THIAZOL-2-AMINE, SUBSTANTIALLY FREE OF DIBROMO IMPURITY AND NOVEL POLYMORPHIC FORMS OF AVATROMBOPAG FREE BASE & IT’S INTERMEDIATE
The present invention relates to an improved process for the preparation of 5-bromo-4-(4-chloroth...
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF AMPHETAMINE AND DERIVATIVES THEREOF:
The present invention relates to an improved process for the preparation of amphetamine and it’s derivatives thereof, using a silane reagent as a hydrogen source, which is economical, green and safe method with simple operation, ...
NOVEL PROCESS FOR THE PREPARATION OF ELACESTRANT AND ITS INTERMEDIATES THEREOF
The present invention relates a novel process for the preparation of elacestrant of formula I or a salt thereof. The present invention particularly relates a novel intermediate compounds, process for the preparation and its use in t...
NOVEL PROCESS FOR THE PREPARATION OF ELACESTRANT AND ITS INTERMEDIATES THEREOF
The present invention relates a novel process for the preparation of elacestrant of formula I or a salt thereof. The present invention particularly relates a novel intermediate compounds, process for the preparation and its use in t...
The present invention relates to an improved process for the preparation of Daprodustat. Specifically, the invention provides a simple, cost-effective, commercially viable, and industrially applicable method for synthesizing Daprodustat of formula I.
Formula I
Registered Trademarks
[Class : 35] Advertising, Liasioning, Import, Export, Distribution, Marketing, Wholesale And Retail Services Relating To Pharmaceutical, Medicinal And Veterinary Preparations; Market Research And Studies In The Field Of Consumer Goods, Advertising, Business Management And Organisation Consulting, Business Management Assistance, Dissemination Of Advertising Materials, Cost Pr...
[Class : 5] Medicinal, Pharmaceutical And Veterinary Preparations Including Dietary, Nutritional And Vitamin Food Supplements
[Class : 44] Medical And Pharmaceutical Research, Design And Development Services; Pharmaceutical Drug Development Services For Third Parties; Pharmaceutical Services, Namely Conducting And Monitoring Clinical Trials And Drug Development; Testing Services In The Field Of Drug Compatibility; Consultancy Services In The Field Of Medical And Pharmaceutical Research, Medical Tre...
View +13 more Brands for Granules India Limited.
Charges
11 June 2019
Idbi Trusteeship Services Limited
780 Crore
10 October 2017
International Finance Corporation
315 Crore
10 October 2017
Deg Deutsche Investitions - Und Entwicklungsgesellschaft Mbh
140 Crore
30 November 2012
International Finance Corporation
52 Crore
30 November 2012
Deg - Deutsche Investitions- Und Entwicklungsgesellschaft Mbh
52 Crore
11 January 1995
A.p.state Financial Corporation
8 Lak
13 November 2002
State Bank Of India
696 Crore
08 February 2014
Andhra Bank
164 Crore
22 December 2007
International Finance Coporation
36 Crore
22 November 2011
International Finance Corporation
4 Crore
30 December 2014
Andhra Bank
20 Crore
25 August 2003
Indian Bank
5 Crore
01 July 2006
Indian Bank
41 Crore
15 April 2010
Bank Of Baroda
8 Crore
22 September 2011
Indusind Bank Ltd
7 Crore
14 September 2012
Andhra Bank
15 Crore
23 April 2002
Andhra Bank
70 Lak
25 November 2005
Ing Vysya Bank Limited
5 Crore
24 October 2005
Export-import Bank Of India
28 Crore
22 September 2011
The Hongkong And Shanghai Banking Corporation Limited
35 Crore
01 October 2005
State Bank Of Travancore
6 Crore
21 October 2008
Kotak Mahindra Bank Limited
4 Crore
31 March 1994
Andhra Pradesh State Financial Corporation
22 Lak
22 September 2005
Ing Vysya Bank
2 Crore
04 February 2004
Ing Vysya Bank
10 Crore
02 June 2005
Indusind Bank Ltd
5 Crore
01 July 2005
Indusind Bank Ltd.
41 Crore
03 January 2000
Andhra Bank
14 Crore
13 December 1996
Andhra Bank
3 Crore
24 October 2005
Andhra Bank
25 Crore
09 August 2003
Andhra Bank
5 Crore
26 March 1997
Andhra Bank
2 Crore
02 March 1998
Andhra Bank
18 Lak
01 June 2005
Andhra Bank
2 Crore
31 August 2005
Andhra Bank
4 Crore
09 May 1998
Andhra Bank
57 Lak
28 April 2004
Andhra Bank
4 Crore
17 March 2006
The Bank Of Baroda Limited
11 Crore
01 July 2005
Indusind Bank Ltd.
1 Crore
12 November 2008
Andhra Bank
25 Crore
02 June 2003
Andhra Bank
2 Crore
04 February 2004
Ing Vysya Bank Limited
4 Crore
31 August 2004
Indian Overseas Bank
1 Crore
05 October 2004
Uco Bank
6 Crore
29 January 2004
The Jammu And Kashmir Bank
10 Crore
08 June 2005
Punjab National Bank
1 Crore
04 July 2002
Punjab Natioal Bank
5 Crore
16 April 2005
Lord Drishna Bank Ltd
3 Crore
06 July 2002
Lord Krishna Bank Ltd
7 Crore
24 September 2004
The Karur Vysya Bank
10 Crore
06 October 2004
The Karur Vysya Bank
2 Crore
07 September 2004
The Karur Vysya Bank
3 Crore
20 June 2005
The Karur Vysya Bank Ltd
1 Crore
29 March 2004
Panjab National Bank
0
29 January 2004
The Jammu And Kashmir Bank
0
05 October 2004
Uco Bank
5 Crore
21 October 2004
Lord Drishna Bank
5 Crore
24 January 2005
Lord Krishna Bank Ltd
1 Crore
04 January 2005
100 Lakshmi Building
5 Crore
03 January 2002
Punjab Natinal Bank
2 Lak
27 December 2002
Uco Bnak
7 Crore
27 December 2002
Uco Bank
2 Crore
22 June 2001
The A.p.vardhaman(mahila) Co-op Urban Bank
50 Lak
11 September 1996
Industrial Development Bank Of India
70 Lak
15 July 1998
Industrial Developmente Bank Of India
4 Crore
02 May 1995
Industrial Development Bank Of India
3 Crore
15 July 1998
Pindustrial Development Bank Of India
4 Crore
30 March 2001
Industrial Development Bank Of India
7 Crore
02 May 1995
Industrial Development Bank Of India
3 Crore
24 July 1992
State Bank Of Hyderabad
36 Lak
15 November 1994
State Bnak Of Hyderabad
2 Crore
10 June 1994
State Bnak Of Hyderabad
32 Lak
10 October 2017
Others
0
10 October 2017
Others
0
01 July 2005
Indusind Bank Ltd.
0
13 November 2002
State Bank Of India
0
11 June 2019
Idbi Trusteeship Services Limited
0
22 September 2011
Indusind Bank Ltd
0
15 November 1994
State Bnak Of Hyderabad
0
30 November 2012
Deg - Deutsche Investitions- Und Entwicklungsgesellschaft Mbh
0
31 August 2004
Indian Overseas Bank
0
01 July 2005
Indusind Bank Ltd.
0
01 October 2005
State Bank Of Travancore
0
24 October 2005
Export-import Bank Of India
0
04 February 2004
Ing Vysya Bank
0
25 November 2005
Ing Vysya Bank Limited
0
31 August 2005
Andhra Bank
0
11 January 1995
A.p.state Financial Corporation
0
02 May 1995
Industrial Development Bank Of India
0
15 July 1998
Pindustrial Development Bank Of India
0
30 March 2001
Industrial Development Bank Of India
0
04 July 2002
Punjab Natioal Bank
0
06 July 2002
Lord Krishna Bank Ltd
0
29 March 2004
Panjab National Bank
0
20 June 2005
The Karur Vysya Bank Ltd
0
10 June 1994
State Bnak Of Hyderabad
0
02 May 1995
Industrial Development Bank Of India
0
09 May 1998
Andhra Bank
0
15 July 1998
Industrial Developmente Bank Of India
0
23 April 2002
Andhra Bank
0
02 June 2005
Indusind Bank Ltd
0
27 December 2002
Uco Bank
0
28 April 2004
Andhra Bank
0
07 September 2004
The Karur Vysya Bank
0
24 January 2005
Lord Krishna Bank Ltd
0
22 September 2011
The Hongkong And Shanghai Banking Corporation Limited
0
12 November 2008
Andhra Bank
0
01 June 2005
Andhra Bank
0
14 September 2012
Andhra Bank
0
01 July 2006
Indian Bank
0
22 December 2007
International Finance Coporation
0
21 October 2008
Kotak Mahindra Bank Limited
0
15 April 2010
Bank Of Baroda
0
22 November 2011
International Finance Corporation
0
30 November 2012
International Finance Corporation
0
08 February 2014
Andhra Bank
0
30 December 2014
Andhra Bank
0
17 March 2006
The Bank Of Baroda Limited
0
29 January 2004
The Jammu And Kashmir Bank
0
24 October 2005
Andhra Bank
0
22 September 2005
Ing Vysya Bank
0
22 June 2001
The A.p.vardhaman(mahila) Co-op Urban Bank
0
31 March 1994
Andhra Pradesh State Financial Corporation
0
11 September 1996
Industrial Development Bank Of India
0
27 December 2002
Uco Bnak
0
02 June 2003
Andhra Bank
0
29 January 2004
The Jammu And Kashmir Bank
0
04 February 2004
Ing Vysya Bank Limited
0
05 October 2004
Uco Bank
0
08 June 2005
Punjab National Bank
0
24 July 1992
State Bank Of Hyderabad
0
13 December 1996
Andhra Bank
0
26 March 1997
Andhra Bank
0
02 March 1998
Andhra Bank
0
03 January 2000
Andhra Bank
0
09 August 2003
Andhra Bank
0
24 September 2004
The Karur Vysya Bank
0
05 October 2004
Uco Bank
0
06 October 2004
The Karur Vysya Bank
0
21 October 2004
Lord Drishna Bank
0
04 January 2005
100 Lakshmi Building
0
16 April 2005
Lord Drishna Bank Ltd
0
03 January 2002
Punjab Natinal Bank
0
25 August 2003
Indian Bank
0
10 October 2017
Others
0
10 October 2017
Others
0
01 July 2005
Indusind Bank Ltd.
0
13 November 2002
State Bank Of India
0
11 June 2019
Idbi Trusteeship Services Limited
0
22 September 2011
Indusind Bank Ltd
0
15 November 1994
State Bnak Of Hyderabad
0
30 November 2012
Deg - Deutsche Investitions- Und Entwicklungsgesellschaft Mbh
0
31 August 2004
Indian Overseas Bank
0
01 July 2005
Indusind Bank Ltd.
0
01 October 2005
State Bank Of Travancore
0
24 October 2005
Export-import Bank Of India
0
04 February 2004
Ing Vysya Bank
0
25 November 2005
Ing Vysya Bank Limited
0
31 August 2005
Andhra Bank
0
11 January 1995
A.p.state Financial Corporation
0
02 May 1995
Industrial Development Bank Of India
0
15 July 1998
Pindustrial Development Bank Of India
0
30 March 2001
Industrial Development Bank Of India
0
04 July 2002
Punjab Natioal Bank
0
06 July 2002
Lord Krishna Bank Ltd
0
29 March 2004
Panjab National Bank
0
20 June 2005
The Karur Vysya Bank Ltd
0
10 June 1994
State Bnak Of Hyderabad
0
02 May 1995
Industrial Development Bank Of India
0
09 May 1998
Andhra Bank
0
15 July 1998
Industrial Developmente Bank Of India
0
23 April 2002
Andhra Bank
0
02 June 2005
Indusind Bank Ltd
0
27 December 2002
Uco Bank
0
28 April 2004
Andhra Bank
0
07 September 2004
The Karur Vysya Bank
0
24 January 2005
Lord Krishna Bank Ltd
0
22 September 2011
The Hongkong And Shanghai Banking Corporation Limited
0
12 November 2008
Andhra Bank
0
01 June 2005
Andhra Bank
0
14 September 2012
Andhra Bank
0
01 July 2006
Indian Bank
0
22 December 2007
International Finance Coporation
0
21 October 2008
Kotak Mahindra Bank Limited
0
15 April 2010
Bank Of Baroda
0
22 November 2011
International Finance Corporation
0
30 November 2012
International Finance Corporation
0
08 February 2014
Andhra Bank
0
30 December 2014
Andhra Bank
0
17 March 2006
The Bank Of Baroda Limited
0
29 January 2004
The Jammu And Kashmir Bank
0
24 October 2005
Andhra Bank
0
22 September 2005
Ing Vysya Bank
0
22 June 2001
The A.p.vardhaman(mahila) Co-op Urban Bank
0
31 March 1994
Andhra Pradesh State Financial Corporation
0
11 September 1996
Industrial Development Bank Of India
0
27 December 2002
Uco Bnak
0
02 June 2003
Andhra Bank
0
29 January 2004
The Jammu And Kashmir Bank
0
04 February 2004
Ing Vysya Bank Limited
0
05 October 2004
Uco Bank
0
08 June 2005
Punjab National Bank
0
24 July 1992
State Bank Of Hyderabad
0
13 December 1996
Andhra Bank
0
26 March 1997
Andhra Bank
0
02 March 1998
Andhra Bank
0
03 January 2000
Andhra Bank
0
09 August 2003
Andhra Bank
0
24 September 2004
The Karur Vysya Bank
0
05 October 2004
Uco Bank
0
06 October 2004
The Karur Vysya Bank
0
21 October 2004
Lord Drishna Bank
0
04 January 2005
100 Lakshmi Building
0
16 April 2005
Lord Drishna Bank Ltd
0
03 January 2002
Punjab Natinal Bank
0
25 August 2003
Indian Bank
0
Documents
Form DPT-3-02022021-signed
Form CHG-1-15122020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201215
Form PAS-3-14122020_signed
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-14122020
Copy of Board or Shareholders? resolution-14122020
Optional Attachment-(3)-14122020
Optional Attachment-(2)-14122020
Instrument(s) of creation or modification of charge;-14122020
Form MR-1-17112020_signed
Copy of shareholders resolution-16112020
Copy of board resolution-16112020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -16112020
Copy of certificate by the Nomination and Remuneration Committee of the company, if any, to the effect that the remuneration is-16112020
Form CHG-4-19102020_signed
Letter of the charge holder stating that the amount has been satisfied-19102020
CERTIFICATE OF SATISFACTION OF CHARGE-20201019
Form MGT-7-03102020_signed
Form PAS-3-29092020_signed
Copy of Board or Shareholders? resolution-29092020
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-29092020
Copy of MGT-8-25092020
Shareholders-MGT_7_R60474772_SAURABH3108_20200925181715.xlsm
Optional Attachment-(1)-25092020
XBRL document in respect Consolidated financial statement-12092020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-12092020
Form AOC-4(XBRL)-12092020_signed
Form MGT-14-20082020_signed
Form MGT-15-20082020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-19082020
